Image credit: Vince Scherer/Shutterstock.com A study published in JAMA Network Open reported that treatment with antidiabetic medicines semaglutide and tirzepatide increases the risk of optic neuropathy and other optic nerve disorders in patients with type 2 diabetes
Details on our oral presentation: #OW2025 To view or add a comment, sign in GLP-1 Drugs Few medical innovations have redefined modern healthcare as rapidly or as broadly as GLP-1 receptor agonists
Retatrutide side effects appear to be dose-related, with higher doses generally linked to more frequent or noticeable symptoms
GLP-1 programs at BodyLase are ideal for adults 18 and older with a BMI of 23 or above, who are motivated to make sustainable lifestyle changes alongside medical support
However, if these side effects last longer than a few weeks or get worse, it is a good idea to talk to a doctor
Results We included 144,384 patients with T2D and a first-time GLP-1 RA prescription during the study period